Licenses and Certifications
Make a Payment
Order a Test
Biotheranostics Announces Inclusion of Breast Cancer Index
in the National Comprehensive Cancer Network (NCCN)
January 19, 2021
Breast Cancer Index (BCI) has reached an incredible milestone as a new standard of care ...
Biotheranostics appoints Mark D. Pegram, MD as Chief Medical Consultant for Breast Oncology
December 29, 2020
Biotheranostics' announces Mark D. Pegram, MD as a Chief Medical Consultant for Breast Oncology for Biotheranostics ...
Breast Cancer Index
demonstrates its ability to predict preferential endocrine benefit irrespective of risk for HR+ early-stage breast cancer patients
December 17, 2020
Evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine benefit ...
Biotheranostics to premiere new data on Breast Cancer Index
and prediction of endocrine therapy benefit at SABCS 2020
December 8, 2020
New data on Biotheranostics' Breast Cancer Index test will be highlighted ...
Biotheranostics' Breast Cancer Index
IDEAL study expands clinical evidence for prediction of extended endocrine benefit to patients treated with aromatase inhibitors
October 29, 2020
Biotheranostics announces the publication of results from the IDEAL study ...
Biotheranostics CancerTYPE ID
aids in patient selection for immunotherapy
September 21, 2020
Biotheranostics announces the publication of a new study evaluating CancerTYPE ID
and its role in identifying subsets of patients ...
Biotheranostics to Present at the LifeSci Partners Summer Symposium
July 27, 2020
Biotheranostics, Inc., a leading healthcare provider in the oncology field with a suite of commercially available proprietary molecular diagnostic tests ...
Biotheranostics presents new studies of the Breast Cancer Index
at the 2020 ASCO conference
May 29, 2020
Biotheranostics announces several new studies demonstrating comprehensive validation and clinical utility of its Breast Cancer Index ...
Biotheranostics’ Breast Cancer Index® predicts benefit from two-and-a-half versus five years of extended endocrine therapy in HR+ breast cancer patients treated in the IDEAL trial
May 15, 2020
Novel evidence demonstrating the ability of Breast Cancer Index to predict preferential endocrine response in distinct subgroups ...
Biotheranostics Announces Chief Commercial Officer
April 1, 2020
On April 1, 2020, company veteran and Vice President of Sales, Matt Sargent, was promoted ...
Biotheranostics’ Pivotal Clinical Study of the Breast Cancer Index® featured on the cover of the Annals of Oncology
February 24, 2020
A pivotal clinical study validating Breast Cancer Index earns the distinction of being selected for the cover of the Annals of Oncology ... ...
Biotheranostics Launches Not Another Minute Campaign for its Breast Cancer Index
December 11, 2019
Biotheranostics, Inc. announces the launch of its Not Another Minute campaign ...
Biotheranostics to Present New Data Expanding the Clinical Utility of Breast Cancer Index® at the 42nd Annual San Antonio Breast Cancer Symposium
December 10, 2019
Biotheranostics, Inc. announced today that several abstracts featuring updates on ongoing research and new data ...